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Can’t Make Head or Tail of it
Readers of the Journal of Developing Drugs are well schooled in 
natural sciences. But few are likely to have time or inclination to dwell 
in the world of economic affairs even though the course of scientific 
discovery is as much influenced by economic events as it shapes the 
unfolding world of future technology. Technology is an endogenous 
variable in neoclassical economics. Its interaction with the economy is 
not fully understood but is known to be the one of the most, if not the 
most, important factor driving long term economic development, jobs 
and prosperity. New technology can quickly reshape the economy. 
Take for example the automobile industry. It grew from virtually 
nothing to a substantial proportion of the economy by mid-century if 
one includes related industries such as tyres, petroleum and repair. Or 
consider development of internet, which accounted for 21 percent of 
GDP growth over the past five years [1]. National health expenditures 
(NHE) are currently 18 percent of the economy but are expected to 
reach 25 percent by 2037 [2]. Is this growth in the health sector a 
blessing or a curse? 
In the United States retail pharmacy expenditures increased from 
4.7 to 9.8 percent of NHE from 1980 to 2010. Much of this growth is 
associated with the spread of health insurance for pharmaceuticals. 
The development of health insurance in the United States was 
originally focused on hospital and physician services. Insurance 
coverage for drugs evolved later, first in the private sector and then in 
the public sector. Coverage for retail prescription drugs for Medicare, 
primarily for those over 65, was implemented as recently as 2006. In 
addition, generous tax provisions exist in the United States shielding 
compensation in the form of health insurance from taxation. 
This further encourages health insurance coverage and medical 
expenditures including for prescription drugs.
There can be little doubt about the importance of new drugs 
in recent decades especially in the academic community. The 5 
year averages of U.S. academic patents by technology area are 
shown below, illustrating large increases in biotechnology and 
pharmaceutical patents in the latter part of the 1990’s that has been 
largely sustained, at least through the first decade of the 21st century. 
The increased availability of new pharmaceuticals and treatment 
options, particularly biologics, will hopefully lead to improved patient 
care and prolonged life (Figure 1).
There is a concurrent, less auspicious perspective focused on how 
beneficial these developments have been for the pharmaceutical and 
pharmacy sectors. Health in the United States, as measured by life 
expectancy and infant mortality, is weak in comparison to other 
developed countries. Health spending should lead to better health and 
one would expect an advanced economy such as the US to excel. Yet 
the World Health Organization (WHO) found that the United States 
fared poorly compared to other countries in the efficiency of its health 
trend line plotting the relationship between per capita income and the 
share of GDP allocated to healthcare using primarily OECD data. The 
United States clearly stands out. 
The US health sector is fragmented and uncoordinated. A key 
source of inefficiency is the wedge between the price consumers pay 
and the cost of production. Economists refer to the moral hazard of 
overconsumption when someone else bears the costs. In the longer 
run moral hazard leads to incentives for new technologies that drive 
up costs, rather than reduce them (Figure 2).
How can these two different narratives be reconciled? The two 
perspectives are not mutually exclusive. Both have veracity. An 
inefficient healthcare sector can generate many jobs and profound 
benefits. But inefficiency initially slows growth, eventually reaching 
a tradeoff: reduce spending or reduce our standard of living in 
non-healthcare sectors. Higher health benefit costs are already an 
important variable in the stagnation of median wages and slowdowns 
in growth in the United States. 
What is to be Done?
In 1902 Vladimir Lenin published “What is to be done?” The 
ambitious revolutionary called for an end to the vacillation of 
the progressive movement and demanded decisive action about 
unacceptable social conditions of his day. Although the Bolsheviks 
certainly provided the Russian public decisive action, many 
decisions were wrong. Health care in some respects faces analogous 
circumstances. Important decisions must be made about what is 
affordable, and more importantly what is beyond affordability. In 
cases where the public is over-insured, markets can be used to address 
these decisions; consumers will vote with their pocket books. For 
more expensive care, decisions will be determined by insurers. But 
these are essentially social decisions and the public sector will need 
to show real leadership. A great risk is that we throw the baby out 
with the bathwater. New technology generating large social benefits 
well in excess of cost should not be stifled, as long as decisions are 
aided with sound cost-effectiveness analyses. Such analyses are found 
in many countries, the most well-known being the United Kingdom 
with its National Institute for Care and Health Excellence (NICE). 
Industry interests in the United States have fiercely resisted reliance 
on cost effectiveness analyses for insurance coverage decisions but 
as a compromise, the US has supported comparative effectiveness 
analyses with emphasis on outcomes rather than costs [4]. The same 
spirit of improving allocative efficiency, that is allocating resources 
across the economy to where they generate the greatest benefit, is 
finding its way to decisions about research funding. Research should 
be directed to topics that hold the greatest promise for the greatest 
good. Of course, research funding has been scarce for a long time 
and subject to scrutiny. But this scrutiny has historically been left to 
*Corresponding author: Peter Hilsenrath, Professor, University of the Pacific, 
USA, Tel: 209-946-2642; E-mail: philsenrath@PACIFIC.EDU
Received June 24, 2013; Accepted June 24, 2013; Published June 28, 2013
Citation: Hilsenrath P, Fischer K (2013) Healthcare Spending: Blessing or Curse. 
J Develop Drugs 2: e125. doi:10.4172/ .1000e125
Copyright: © 2013 Hilsenrath P, et al. This is an open-access article distributed 
under the terms of the Creative Commons Attribution License, which permits un-
restricted use, distribution, and reproduction in any medium, provided the original 
author and source are credited.
Healthcare Spending: Blessing or Curse
Peter Hilsenrath* and Katrina Fischer
University of the Pacific, USA
spending [3]. Figure 1 illustrates relatively high US spending with a 
Citation: Hilsenrath P, Fischer K (2013) Healthcare Spending: Blessing or Curse. J Develop Drugs 2: e125. doi:10.4172/2329-6631.1000e125
Page 2 of 2
Volume 2 • Issue 2 • 1000e125
J Develop Drugs
ISSN: 2329-6631   JDD, an open access journal 
the scientific community. In some European countries, this process 
is becoming more pluralistic with input from outside the scientific 
community. The United States can be expected to follow suit. 
Another important element to reforming R&D funding is a 
new focus on productive efficiency. Productive efficiency describes 
producing a product for a given quantity and quality at the lowest 
cost possible. This kind of efficiency is well understood by managers 
throughout the American economy, except in the health sector (with 
some incipient signs of change not withstanding). Industrial research 
commonly seeks lower cost and higher quality products, yet this 
culture is alien to most academic health science centers in the United 
States. How many academic health researchers look for new ways to 
provide less costly care and products? Game changing innovation 
more commonly comes from the private sector with little, if any 
support from established players in health. This state of affairs is not 
likely to persist indefinitely and research funding can be expected to 
lend greater support to gains in productive efficiency. 
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Figure 2: NHE as share of GDP.
